Intercept Pharmaceuticals vs. Zenara Pharma: ANDA Patent Consolidation in FXR Agonist Litigation
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Intercept Pharmaceuticals, Inc. v. Zenara Pharma Private, Ltd. |
| Fallnummer | 1:23-cv-00714 (D. Del.) |
| Gericht | District of Delaware, before Judge Maryellen Noreika |
| Dauer | June 30, 2023 – March 6, 2024 250 days |
| Ergebnis | Procedural Resolution – Consolidation |
| Streitige Patente | |
| Beschuldigte Produkte | Zenara Pharma’s proposed generic version of Ocaliva® (obeticholic acid) |
Fallübersicht
Die Parteien
⚖️ Kläger
Innovator pharmaceutical company and developer of Ocaliva® (obeticholic acid), a key FXR agonist therapy for primary biliary cholangitis (PBC).
🛡️ Beklagter
Generic pharmaceutical manufacturer seeking regulatory approval for a generic version of Ocaliva® via an ANDA pathway.
Das streitige Patent
This Hatch-Waxman infringement action centered on **U.S. Patent No. RE48,286**, a reissue patent covering steroids as agonists for the Farnesoid X Receptor (FXR), the active mechanism behind Intercept’s branded bile acid therapy Ocaliva® (obeticholic acid). Reissue patents are granted by the USPTO to correct defects in originally issued patents.
- • US RE48,286 — Steroids as agonists for FXR (Farnesoid X Receptor)
Entwicklung eines ähnlichen pharmazeutischen Wirkstoffs?
Identify potential blocking patents in the FXR agonist space before development.
Das Urteil und die rechtliche Analyse
Ergebnis
This case was resolved through **consolidation**, not a trial verdict or settlement on the merits. The action (1:23-cv-00714) was merged into the lead case (C.A. No. 22-1215) for all purposes. No damages were awarded, and no injunctive relief was independently granted within this docket — the substantive merits of infringement and validity remain live issues within the consolidated proceeding.
Wichtige rechtliche Fragen
The consolidation reflects several critical legal and strategic dynamics. The most significant outcome is the **extension of Hatch-Waxman exclusivity protection**. By timely suing on RE48,286, Intercept secured a *separate* 30-month stay running to December 21, 2025, effectively delaying potential generic market entry. This also streamlined a complex multi-patent dispute under a unified protective order and scheduling framework before Judge Maryellen Noreika in the District of Delaware.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in pharmaceutical development, especially in the FXR agonist space. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Arzneimittelprozesses.
- View all 7 related Ocaliva® patents
- Analyze Intercept’s patent portfolio for FXR agonists
- Understand Hatch-Waxman stay architecture
🔍 Das Risiko meines Produkts überprüfen
Run a comprehensive FTO analysis for your own pharmaceutical compound or drug product.
- Input your compound structure or mechanism of action
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie eine umsetzbare Bewertung des Verletzungsrisikos
Hochrisikogebiet
FXR agonist compounds and methods
Extended Stay Secured
Until December 2025 for RE48,286
Consolidated Discovery
Efficiency for multi-patent suits
✅ Wichtigste Erkenntnisse
Timely assertion against successively filed Paragraph IV certifications can yield independent 30-month stays, extending exclusivity.
Ähnliche Hatch-Waxman-Fälle suchen →Reissue patents introduce unique validity risks (recapture, intervening rights) for generic challengers to assess.
Entdecken Sie die Analyse von Patentneuanmeldungen →Häufig gestellte Fragen
The case involved U.S. Patent No. RE48,286, a reissue patent covering steroids as agonists for FXR, listed in the Orange Book for Ocaliva® (obeticholic acid). The consolidated lead case (C.A. No. 22-1215) involves six additional Orange Book patents.
The parties stipulated to consolidation for judicial efficiency. All substantive infringement and validity issues relating to RE48,286 are being litigated within the lead case, C.A. No. 22-1215, before Judge Noreika.
It demonstrates that successive Orange Book patent listings paired with timely Hatch-Waxman suits can extend stay protections by years, materially delaying generic competition in specialty pharmaceutical markets.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- PACER Case Docket – C.A. No. 22-1215 (D. Del.)
- USPTO Patent RE48,286
- FDA Orange Book – Ocaliva®
- U.S. Patent and Trademark Office — Reissue Patent Resources
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.